Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

345.73
+3.441.00%
Post-market: 351.005.27+1.52%19:59 EDT
Volume:355.25K
Turnover:122.48M
Market Cap:7.71B
PE:-26.98
High:348.34
Open:340.98
Low:339.31
Close:342.29
52wk High:377.46
52wk Low:200.63
Shares:22.29M
Float Shares:11.00M
Volume Ratio:0.68
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8155
EPS(LYR):-21.9007
ROE:-36.30%
ROA:-18.31%
PB:11.07
PE(LYR):-15.79

Loading ...

Madrigal Pharmaceuticals Inc - CSPC Grants Madrigal Global License for Syh2086 With $120 Mln Upfront

THOMSON REUTERS
·
Jul 30

Madrigal Pharmaceuticals Inc - to Initiate Clinical Development in First Half of 2026

THOMSON REUTERS
·
Jul 30

Madrigal Pharmaceuticals Inc - CSPC Eligible for up to $2 Bln in Milestone Payments

THOMSON REUTERS
·
Jul 30

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

GlobeNewswire
·
Jul 25

Madrigal Pharmaceuticals: Strategic Financing and Growth Potential Justify Buy Rating

TIPRANKS
·
Jul 23

Rebecca Taub, Director, Reports Disposal of Madrigal Pharmaceuticals Inc. Common Shares

Reuters
·
Jul 23

Paul A. Friedman, Director, Reports Disposal of Common Shares of Madrigal Pharmaceuticals Inc

Reuters
·
Jul 23

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

GlobeNewswire
·
Jul 22

Citizens JMP Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
Jul 22

Director Paul A. Friedman Reports Disposal of Common Shares in Madrigal Pharmaceuticals Inc

Reuters
·
Jul 19

Rebecca Taub, Director, Reports Disposal of Common Shares in Madrigal Pharmaceuticals Inc

Reuters
·
Jul 19

Canaccord Genuity Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
Jul 17

U.S. RESEARCH ROUNDUP-Bank of America, Goldman Sachs, Microsoft

Reuters
·
Jul 17

Oppenheimer Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
Jul 17

Madrigal patent for Rezdiffra ‘significant win,’ says Piper Sandler

TIPRANKS
·
Jul 16

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

GlobeNewswire
·
Jul 16

Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term

Simply Wall St.
·
Jul 09

Madrigal Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 21

Positive CHMP Opinion Boosts Madrigal Pharmaceuticals’ Prospects for Rezdiffra in EU Market

TIPRANKS
·
Jun 21

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires Live
·
Jun 20